新辅助奥希替尼治疗I-IIIA期表皮生长因子受体突变非小细胞肺癌:一项II期多中心研究
这项多中心II期试验评估新辅助奥希替尼用于可手术切除的I-IIIA期EGFR突变(L858R或外显子19缺失)非小细胞肺癌患者,共27例接受80mg每日一次口服最多两个28天周期后手术。主要终点主要病理缓解(MPR)率为14.8%(95%CI 4.2-33.7),未达到主要终点;客观缓解率52%,中位无病生存期40.9个月。
要点
- 新辅助奥希替尼治疗可手术EGFR突变NSCLC的MPR率为14.8%(95%CI 4.2-33.7),未达到主要终点。
- 24例(89%)完成手术,3例(11%)转为根治性放化疗,无患者因不良事件无法手术或手术延迟。
- 客观缓解率52%,中位无病生存期40.9个月,1例(3.7%)发生治疗相关严重不良事件。
核心结论
- 新辅助奥希替尼治疗可手术切除的IA-IIIA期(AJCC第7版)EGFR突变NSCLC未达到主要终点MPR率。
- 新辅助奥希替尼未导致意外不良事件、手术延迟,也未导致显著不可切除率。
研究设计与样本
- 多中心II期试验(ClinicalTrials.gov NCT03433469),纳入可手术切除的I-IIIA期(AJCC第7版)EGFR突变(L858R或外显子19缺失)NSCLC患者。
- 患者术前接受奥希替尼80mg口服每日一次,最多两个28天周期,共27例入组并治疗,中位治疗56天后手术。
- 主要终点为MPR率,次要终点评估安全性和疗效,探索性终点包括治疗前后肿瘤突变谱分析。
主要发现
- 24例(89%)患者接受后续手术,3例(11%)转为根治性放化疗。
- MPR率为14.8%(95%CI 4.2-33.7),未观察到病理完全缓解。
- 客观缓解率为52%,中位无病生存期为40.9个月。
- 1例(3.7%)发生治疗相关严重不良事件,无患者因不良事件无法手术或手术延迟。
- 最常见的共存肿瘤基因组改变为TP53(42%)和RBM10(21%)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To assess the safety and efficacy of the third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor osimertinib as neoadjuvant therapy in patients with surgically resectable stage I-IIIA EGFR-mutated non-small cell lung cancer (NSCLC). PATIENTS AND METHODS: This was a multi-institutional phase II trial of neoadjuvant osimertinib for patients with surgically resectable stage I-IIIA (American Joint Committee on Cancer [AJCC] V7) EGFR-mutated (L858R or exon 19 deletion) NSCLC (ClinicalTrials.gov identifier: NCT03433469). Patients received osimertinib 80 mg orally once daily for up to two 28-day cycles before surgical resection. The primary end point was major pathological response (MPR) rate. Secondary safety and efficacy end points were also assessed. Exploratory end points included pretreatment and post-treatment tumor mutation profiling. RESULTS: A total of 27 patients were enrolled and treated with neoadjuvant osimertinib for a median 56 days before surgical resection. Twenty-four (89%) patients underwent subsequent surgery; three (11%) patients were converted to definitive chemoradiotherapy. The MPR rate was 14.8% (95% CI, 4.2 to 33.7). No pathological complete responses were observed. The ORR was 52%, and the median DFS was 40.9 months. One treatment-related serious adverse event (AE) occurred (3.7%). No patients were unable to undergo surgical resection or had surgery delayed because of an AE. The most common co-occurring tumor genomic alterations were in TP53 (42%) and RBM10 (21%). CONCLUSION: Treatment with neoadjuvant osimertinib in surgically resectable (stage IA-IIIA, AJCC V7) EGFR-mutated NSCLC did not meet its primary end point for MPR rate. However, neoadjuvant osimertinib did not lead to unanticipated AEs, surgical delays, nor result in a significant unresectability rate.
引用
- Blakely CM, Urisman A, Gubens MA, et al. Neoadjuvant Osimertinib for the Treatment of Stage I-IIIA Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: A Phase II Multicenter Study. J Clin Oncol. 2024. PMID: 39028931. doi:10.1200/JCO.24.00071
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。